Ponatinib and blinatumomab improve outcomes in acute lymphoblastic leukemia
- Ponatinib and blinatumomab improve outcomes in acute lymphoblastic leukemia
- Izalontamab brengitecan slowed advanced non-small cell lung cancer
- FDA approves amivantamab for head and neck cancer
- Experts to discuss chest CT screening for lung cancer
- MTAP loss linked to immunotherapy response in pleural mesothelioma
- Targeted scans found more clear cell kidney cancer lesions
Ponatinib and blinatumomab improve outcomes in acute lymphoblastic leukemia
In a trial of 236 adults with newly diagnosed acute lymphoblastic leukemia, ponatinib plus blinatumomab significantly improved event-free survival compared with imatinib plus chemotherapy.
Why it matters. A large, final-stage trial in acute lymphoblastic leukaemia, a blood cancer. This is the kind of result regulators use when deciding whether to approve a treatment.
The ASCO Post, 6 Nov 2026 · Phase III human clinical trial | 236 adultsIzalontamab brengitecan slowed advanced non-small cell lung cancer
In a phase III trial, people with advanced non-small cell lung cancer that had grown after targeted treatment received izalontamab brengitecan or chemotherapy. The cancer took 11.1 months to grow with the drug, compared with 5.7 months with chemotherapy.
Why it matters. A large, final-stage trial in lung cancer. This is the kind of result regulators use when deciding whether to approve a treatment.
The ASCO Post, 6 Nov 2026 · Phase III human clinical trial | 432 patientsFDA approves amivantamab for head and neck cancer
The FDA approved amivantamab with hyaluronidase for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and immune treatment. In a trial of 102 patients, tumors shrank in 42%; among those patients, 56% had responses lasting at least 6 months.
Why it matters. Approved by the US Food and Drug Administration (FDA) for lung cancer. Doctors can now prescribe it outside a trial.
The ASCO Post, 6 Nov 2026 · Regulatory approval | 102 patientsExperts to discuss chest CT screening for lung cancer
Experts from health, research and advocacy groups will meet virtually to discuss using low-dose chest CT to detect lung cancer and other chest diseases early.
Why it matters. Based on data or samples from people with lung cancer. It is not a treatment trial.
The ASCO Post, 6 Nov 2026 · Human observational studyMTAP loss linked to immunotherapy response in pleural mesothelioma
In two groups of people with malignant pleural mesothelioma, researchers found that MTAP loss was linked to more responses to immune therapy in one group. The response rate was 29.4% in that group.
“MTAP loss was linked to immune-related features and a higher immune checkpoint inhibitor response, supporting further investigation of MTAP loss as a candidate biomarker.”
Why it matters. Based on data or samples from people with mesothelioma. It is not a treatment trial.
Clinical Cancer Research, 6 Nov 2026 · Human observational study | 52 patientsTargeted scans found more clear cell kidney cancer lesions
In a study of people with clear cell kidney cancer, the CD70-targeted scan found 88.7% of cancer lesions, compared with 76.1% for the PSMA-targeted scan. It found more cancer in the lungs and liver.
“Therefore, it represents a valuable complement to existing imaging modalities for ccRCC.”
Why it matters. Based on data or samples from people with kidney cancer. It is not a treatment trial.
Clinical Cancer Research, 6 Nov 2026 · Human observational study | 128 patientsDeals and stopped trials
- FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCCascopost.com
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerTerminated · Phase III · Novartis Pharmaceuticals · Reason given: Business reasons and not based on any safety concerns.
New trials
- Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid TumorsRadiopharmaceuticals · Phase I · 12 people · Hexin (Suzhou) Pharmaceutical Technology Co., Ltd · China
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaAntibody-drug conjugates · Phase II · 60 people · M.D. Anderson Cancer Center · United States
Worth watching
- FDA approves amivantamab for previously treated head and neck cancerThe FDA granted accelerated approval for amivantamab and hyaluronidase for adults with recurrent or metastatic head and neck cancer after platinum chemotherapy and immunotherapy. In a trial of 102 patients, 42% had their cancer shrink; 56% of those responses lasted at least 6 months.
- One scan found more clear cell kidney cancer lesionsResearchers compared two types of scans in people with kidney cancer. Among 36 patients who had both scans, one found 88.7% of clear cell kidney cancer lesions, compared with 76.1% for the other.
- Patient-Provider Communication, Treatment, and Survival in a Population-Based Cohort: The North Carolina-Louisiana Prostate Cancer ProjectResearch finding, JCO Oncology Practice, 6 Nov 2026